Edition:
United Kingdom

PLx Pharma Inc (PLXP.OQ)

PLXP.OQ on NASDAQ Stock Exchange Capital Market

6.80USD
4:57pm GMT
Change (% chg)

$-0.10 (-1.45%)
Prev Close
$6.90
Open
$6.85
Day's High
$6.85
Day's Low
$6.80
Volume
195
Avg. Vol
4,632
52-wk High
$21.60
52-wk Low
$5.60

Latest Key Developments (Source: Significant Developments)

Park West Asset Management reports 12.3 pct stake in PLx Pharma
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Park West Asset Management Llc::Park West Asset Management Llc reports 12.3 percent stake in PLx Pharma Inc ‍​as of November 20 - SEC filing.Park West Asset Management-anticipates engaging in discussions with PLx Pharma management,members of board concerning potential financing transactions.  Full Article

PLx Pharma Inc. Reports third quarter 2017 results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Plx Pharma Inc :PLx Pharma Inc. reports third quarter 2017 results.Q3 loss per share $0.44.  Full Article

Dipexium announces top-line data from onestep phase 3 trials
Tuesday, 25 Oct 2016 

Dipexium Pharmaceuticals Inc : Announces top-line data from onestep phase 3 trials with locilex in mild diabetic foot infection did not meet primary clinical endpoint of superiority versus vehicle plus standardized wound care . Top-line data from onestep phase 3 trials with locilex in mild diabetic foot infection did not meet primary clinical endpoint .Serious adverse events with locilex included higher than anticipated osteomyelitis and cellulitis in locilex arm of each study.  Full Article

Dipexium Pharmaceuticals Q2 loss per share $0.52
Thursday, 4 Aug 2016 

Dipexium Pharmaceuticals Inc : Dipexium Pharmaceuticals reports second quarter 2016 financial results . Q2 loss per share $0.52 .Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.  Full Article

Dipexium pharmaceuticals posts Q1 loss per share $0.56
Thursday, 12 May 2016 

Dipexium Pharmaceuticals Inc : Announces Completion Of Enrollment Objective In Onestep 2 pivotal phase 3 clinical trial and first quarter 2016 financial results . Dipexium Pharmaceuticals Inc qtrly loss per share $0.56 . Company's cash balance is currently anticipated to fund operations through 2017 .Line data from pivotal phase 3 clinical trials in q3 of 2016.  Full Article

BRIEF-Park West Asset Management reports 12.3 pct stake in PLx Pharma

* Park West Asset Management Llc reports 12.3 percent stake in PLx Pharma Inc ‍​as of November 20 - SEC filing